STOCK TITAN

Viatris Inc. - VTRS STOCK NEWS

Welcome to our dedicated page for Viatris news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company that bridges the gap between generics and branded medicines, aiming to address healthcare needs more comprehensively worldwide. Formed in November 2020 by the merger of Upjohn, a subsidiary of Pfizer, and Mylan, Viatris leverages its vast portfolio to provide high-quality medications to approximately 1 billion patients annually across more than 165 countries. The company’s operations span 10 major therapeutic areas, with a strategic focus on dermatology, ophthalmology, and gastroenterology.

Viatris boasts an extensive product lineup, including around 1,400 generic pharmaceuticals and several branded medications like Lipitor, Norvasc, Lyrica, and Viagra. Generics and biosimilars form about 40% of its sales, while legacy products contribute to the remaining 60%. The company is also a key supplier of antiretroviral therapies, which nearly 50% of HIV/AIDS patients in developing countries rely on.

In 2023, Viatris continued to make strides with significant developments. It announced positive results from the YUPELRI® Phase III clinical trial in China for COPD treatment, paving the way for regulatory approval anticipated in mid-2024. The company also entered a substantial R&D collaboration with Idorsia Ltd, acquiring global rights to two promising Phase 3 assets: selatogrel, for acute myocardial infarction, and cenerimod, for systemic lupus erythematosus. Additionally, Viatris launched RYZUMVI™, an FDA-approved eye drop for reversing pharmacologically-induced dilation, further expanding its ophthalmology portfolio.

Financially, Viatris demonstrated robust performance with consistent operational revenue growth. The company reported a strong 2023, meeting its financial guidance, and executed strategic initiatives like the divestiture of its Women's Healthcare Business and API business in India. Viatris also maintained a solid cash flow, allowing it to return capital to shareholders through dividends and share repurchases, reinforcing its commitment to shareholder value.

Headquartered in the U.S., with major centers in Pittsburgh, Shanghai, and Hyderabad, Viatris employs around 30,000 people dedicated to advancing global health. For more information, visit viatris.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
none
Rhea-AI Summary
Viatris Inc. reported total revenues of $3.73 billion, U.S. GAAP net earnings of $225 million, adjusted EBITDA of $1.34 billion, U.S. GAAP net cash provided by operating activities of $971 million, and free cash flow of $923 million for the first quarter of 2023. The company expects full-year total revenues, adjusted EBITDA, and free cash flow to be at the midpoint of its 2023 guidance ranges. Viatris returned approximately $400 million of capital to shareholders through dividends and share repurchases in the first quarter and paid down debt of $546 million. The company also declared a quarterly dividend of $0.12 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
-
Rhea-AI Summary

Viatris Inc. (NASDAQ: VTRS) and Mapi Pharma announced the presentation of recent clinical findings regarding GA Depot at the American Academy of Neurology (AAN) 75th Annual Meeting in Boston from April 22-27, 2023. The pivotal Phase III clinical trial analyzes the efficacy and safety of GA Depot, a long-acting glatiramer acetate for treating relapsing forms of multiple sclerosis (RMS). Viatris emphasizes its commitment to improving healthcare access for MS patients through innovative solutions. The poster session details include research results to be presented on April 24, 2023, from 5:30 to 6:30 p.m. EST.

Viatris is dedicated to providing high-quality medicines globally, with a portfolio of over 1,400 approved molecules across various therapeutic areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
-
Rhea-AI Summary

Viatris Inc. (NASDAQ: VTRS) will report its first quarter 2023 financial results on May 8, 2023, before the markets open. CEO Scott Smith, President Rajiv Malik, and CFO Sanjeev Narula will host a webcast at 8:30 a.m. ET on the same day to discuss the results. Investors can access the live webcast at investor.viatris.com or by calling 800-579-2543. A replay will also be available on their website. Founded in November 2020, Viatris focuses on providing access to medicines globally. The company operates in over 165 countries and boasts a portfolio of more than 1,400 approved medicines across a wide range of therapeutic areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
conferences earnings
Rhea-AI Summary

Viatris Inc. (NASDAQ: VTRS) has collaborated with the American College of Cardiology to launch the "Health Equity and Social Determinants of Health in NCDs" course on the NCD Academy, coinciding with World Health Day. This initiative aims to equip healthcare professionals with resources to tackle non-communicable diseases (NCDs), which account for over 70% of global deaths. The program is part of Viatris' commitment to health equity, supporting its goal to educate 100 million patients by 2025. Launched in 2020, the NCD Academy now offers nearly comprehensive training on various NCDs, addressing mental health and advocacy as well. The course rollout started in April, highlighting the importance of equitable healthcare for vulnerable communities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none

FAQ

What is the current stock price of Viatris (VTRS)?

The current stock price of Viatris (VTRS) is $12.52 as of December 20, 2024.

What is the market cap of Viatris (VTRS)?

The market cap of Viatris (VTRS) is approximately 14.7B.

What is Viatris Inc.?

Viatris Inc. is a global healthcare company formed by the merger of Upjohn and Mylan, providing a wide range of generic and branded medications.

What products does Viatris offer?

Viatris offers around 1,400 generic pharmaceuticals and several branded medications like Lipitor, Norvasc, Lyrica, and Viagra.

What are Viatris' key therapeutic areas?

Viatris focuses on 10 major therapeutic areas, with special emphasis on dermatology, ophthalmology, and gastroenterology.

What recent collaborations has Viatris announced?

Viatris announced a significant R&D collaboration with Idorsia Ltd, acquiring global rights to two Phase 3 assets: selatogrel and cenerimod.

How did Viatris perform financially in 2023?

Viatris demonstrated strong financial performance in 2023, meeting its guidance and achieving consistent operational revenue growth.

Where is Viatris headquartered?

Viatris is headquartered in the United States, with major global centers in Pittsburgh, Shanghai, and Hyderabad, India.

What is YUPELRI®?

YUPELRI® is a once-daily nebulized long-acting muscarinic antagonist (LAMA) for COPD maintenance treatment, showing positive results in a Phase III trial in China.

What is the significance of RYZUMVI™?

RYZUMVI™ is an FDA-approved eye drop launched by Viatris for reversing pharmacologically-induced dilation, expanding its ophthalmology portfolio.

What is the mission of Viatris?

Viatris aims to empower people worldwide to live healthier lives by providing access to high-quality medicines at scale, addressing healthcare needs globally.

How many people does Viatris employ?

Viatris employs approximately 30,000 people dedicated to advancing global health.

Viatris Inc.

Nasdaq:VTRS

VTRS Rankings

VTRS Stock Data

14.66B
1.19B
0.41%
82.85%
1.74%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
CANONSBURG